Showing 3121-3130 of 6035 results for "".
- Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/Ocular Therapeutix announced that it has dosed the first patients in its phase 3 clinical trial of Dextenza for the treatment of symptoms of allergic conjunctivitis. Allergic conjunctivitis refers to inflammation of the conjunctiva of the eye caused by an allergic reaction–generally from airborne
- Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driverhttps://modernod.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/The world’s aging population—leading to steady growth in cataract surgeries—and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmic surgical product mar
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseaseshttps://modernod.com/news/boehringer-ingelheim-partners-with-inflammasome-therapeutics-to-develop-novel-therapies-for-patients-with-retinal-diseases/2476903/Boehringer Ingelheim and Inflammasome Therapeutics announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelhei
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- Canon Xephilio OCT-A1 Device Receives FDA 510(k) Clearancehttps://modernod.com/news/canon-xephilio-oct-a1-device-receives-fda-510k-clearance/2476889/Expanding the company’s lineup of eye care product offerings, Canon USA announced the new intuitive Xephilio OCT-A1 device. This device features automated acquisition functionality, which makes it easy to use, allowing healthcare professionals to obtain high
- Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Boardhttps://modernod.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/Oculis SA announced the appointments of Eric Donnenfeld, MD, and Pr. Ramin Tadayoni, MD, PhD, to its Scientific Advisory Board (SAB). “I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that
- Cassini to Reveal New Cassini Device at ESCRShttps://modernod.com/news/cassini-to-reveal-new-cassini-device-at-the-escrs-in-paris/2476880/Cassini announced that it will reveal its new Cassini device at the 37th Congress of European Society of Cataract and Refractive Surgeons in Paris. This product introduction marks the next chapter of product design, with latest camera technology, improved patient comfort and great usability.
- Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for Wet AMDhttps://modernod.com/news/kodiak-sciences-to-release-durability-data-from-clinical-development-program-of-ksi-301-for-wet-amd/2476877/Kodiak Sciences announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London. “Developing intra
- Macular Degeneration Conference Series in the Spotlighthttps://modernod.com/news/macular-degeneration-conference-series-in-the-spotlight/2476865/Part of the 2019 Macular Degeneration Association Educational Conference Series will take place on Saturday, September 21, at the Doubletree Chicago North Shore Conference Center Skokie, Illinois. The conference, “Eyes on Sight,” is aimed to deliver the most up-to-date research regarding t
- ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2479540/ProQR Therapeutics announced that it received fast track designation from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation